Prot# AT1001-011: A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients with Fabry Disease and AT1001-Responsive GLA Mutations

Project: Research project

StatusFinished
Effective start/end date4/29/114/29/14

Funding

  • Ann & Robert H. Lurie Children's Hospital of Chicago (AT1001-011)
  • Amicus Therapeutics, Inc. (AT1001-011)